Health Condition 1: E11- Type 2 diabetes mellitus
Conditions
Interventions
Intervention1: FDC of Dapagliflozin, Sitagliptin, Metformin HCl Tablets (5 mg, 50 mg and 1000 mg OR 5 mg, 50 mg and 500 mg): One tablet of FDC of Dapagliflozin, Sitagliptin and Metformin HCl 5 mg 50 m
Sponsors
Sun Pharma Laboratories Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients of either gender, aged 18 to 65 years (both inclusive) and ready to give written informed consent to participate in the study at the time of screening 2) Patients with documented diagnosis of type 2 diabetes mellitus 3) Patients along with diet and exercise control, and on FDC of Sitagliptin and Metformin (50 mg+500 mg) OR (50 mg + 1000 mg) twice daily (BID) for at least 8 weeks prior to screening 4) Patients with Glycated hemoglobin (HbA1c) >=7.5% to 5) Patients with body mass index (BMI) 6) Women of childbearing potential must have a negative urine pregnancy test prior to study entry and agree to use highly effective methods of contraception to prevent pregnancy from study entry till at least two weeks after the last dose of the study medication (such contraception may include hormonal birth control e.g., combined estrogen and progestogen containing [oral, intravaginal, or transdermal] or progesterone only [oral, injectable, or implantable] hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone releasing system OR bilateral tubal occlusion, vasectomized partner, or total sexual abstinence) [Note: Women with childbearing potential are defined as: those who are not (1) surgically sterile (bilateral oophorectomy, hysterectomy, or bilateral tubal ligation) or (2) post-menopausal. Post-menopausal woman will be defined as: Woman not using hormonal replacement therapy and have had at least 12 continuous months of natural (spontaneous) amenorrhea and be greater than 45 years of age.]
Exclusion criteria
Exclusion criteria: 1. Patients with documented diagnosis of type 1 diabetes, diabetes insipidus, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes (e.g. Cushing syndrome or acromegaly- associated diabetes) 2. Patients with Fasting Blood Glucose (FBG) >= 270 mg/dL at screening (if required, measurement can be repeated and confirmed within 7 days) 3. Patients with history of hypersensitivity to any of the study drug or to drugs of similar chemical classes (e.g. sulfonamide) or to any of its excipients 4. Patients with administration of any therapy for diabetes, other than Metformin and Sitagliptin during the 8 weeks prior to screening 5. Patients with history of taking any weight loss medications within 3 months prior to randomization 6. Patients planning to take any anti-diabetic drugs or weight loss drugs other than study drugs or rescue medication during the study 7. Treatment with glucocorticoids equivalent to oral prednisolone >= 10 mg (betamethasone >= 1.2 mg, dexamethasone >= 1.5 mg, hydrocortisone >= 40 mg) per day within 30 days prior to randomization; topical, nasal or inhaled corticosteroids are allowed 8. Patients with history of Human immunodeficiency virus (HIV) and/or Hepatitis B virus (HBV) and/ or Hepatitis C virus (HCV) 9. Patients having significant renal (estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2) or hepatic impairment (aspartate transaminase [AST] and alanine transaminase [ALT] Ë? 3 x upper limit of normal [ULN]) 10. Patients taking loop diuretics within one week prior to screening or planning to take during the study 11. Patients suffering with end-stage renal disease or on dialysis 12. Any condition (e.g. infection, trauma, surgery) which require insulin therapy at the time of screening or during the study period. Short term use i.e. 13. History of bariatric surgery (i.e. any surgery to treat obesity; for example, gastric banding or procedures that involve bypassing or transposing sections of the small intestine). History of liposuction is allowed 14. Patients having history of acute or chronic metabolic acidosis, including diabetic ketoacidosis and lactic acidosis, pancreatitis or hyperosmolar state (including coma) 15. Patients having history or currently suffering with severe and disabling arthralgia 16. Patients who are lactose intolerant 17. Patients suffering from severe urinary tract infections (e.g. urosepsis, pyelonephritis), necrotizing fasciitis of the perineum (Fournierâ??s gangrene), intravascular volume contraction and/ or female genital mycotic infections prior to 6 months from screening. 18. Patients having history or currently suffering with bullous pemphigoid requiring hospitalization 19. Patients with history of myocardial infarction, coronary artery bypass surgery or percutaneous coronary intervention, stroke or transient ischemic attack prior to 6 months from screening 20. Patients with history of unstable angina prior to 3 months from screening 21. Patients with history of sustained and clinically relevant ventricular arrhythmia 22. Any of the following electrocardiogram (ECG) abnormalities: - Second or third degree atrio-ventricular (AV) block without a pacemaker - Long QT syndrome or QTc > 500 ms 23. Patients having history or currently sufferi
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in HbA1c from baseline at the end of Week 16Timepoint: baseline at the end of Week 16 | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy 1. Mean change in HbA1c from baseline at the end of Week 12 2. Mean change in Postprandial Blood Glucose (PPBG) from baseline at the end of Week 12 and Week 16 3. Mean change in FBG from baseline at the end of Week 12 and Week 16 4. Proportion of patients achieving HbA1c 7.0% at the end of Week 12 and Week 16 5. Mean change in body weight from baseline to end of Week 16 6. Number of patients requiring rescue medications Safety 1. Safety assessment includes Treatment-Emergent Adverse Events (TEAEs) reported during the study 2. Number of patients requiring hypoglycemia managementTimepoint: Efficacy 1. Baseline and week 12 2. Baseline, week 12 and week 16 3. Baseline, week 12 and week 16 4. Baseline, week 12 and week 16 5. Baseline, week 16 6. At each visit Safety 1. At each visit 2. At each visit number of subjects requirs hypoglycemia management | — |
Countries
India
Contacts
Public ContactRajesh Gaikwad
Sun Pharma Laboratories Limited
Outcome results
None listed